Two Major Doctor Groups Endorse Hormone Therapy as First-Line Menopause Treatment

For two decades, hormone therapy for menopause carried black-box warnings that scared off patients and doctors alike. This month, the American College of Obstetricians and Gynecologists made it a first-line treatment.

The new guidelines, released in 2026, strongly recommend systemic menopausal hormone therapy for hot flashes, night sweats and related sleep disturbances in eligible women — a reversal of the cautious stance that followed the Women’s Health Initiative. In October, the American College of Physicians issued its own endorsement of hormone therapy as first-line treatment for the same symptoms, meaning the two largest groups of women’s physicians are now saying the same thing.

“The American College of Obstetricians and Gynecologists statement tells OB-GYNs that hormone replacement therapy is part of their standard of care,” said Dr. Cynthia Chuang, a women’s health and internal medicine physician at Penn State Health Cocoa Outpatient Center. “The American College of Physicians statement is telling internists the same thing. This is part of what we do.”

Chuang, who leads Penn State Health’s Menopause Clinic, said the guidelines followed a thorough evidence review. “They did a comprehensive review of the research and literature around vasomotor symptoms and sleep disturbances related to vasomotor symptoms,” she said. “This really elevates it and says that unless you have risk factors that don't allow you to take hormone therapy for some reason, they recommend systemic menopausal hormone therapy.”

How 2002 Changed Everything

Before 2002, HRT was a routine prescription. That changed when the Women’s Health Initiative published results that year tying the estrogen-plus-progestin regimen under study to elevated risks of breast cancer, cardiovascular disease, stroke and pulmonary embolism. Those findings led to black-box warnings and a sharp decline in use, as many physicians turned to nonhormonal treatments.

A woman wearing a striped T-shirt holds a package of hormone therapy pills
Photo: Tufts Now

In November 2025, the tide started to turn: the FDA, having examined newer studies, directed drugmakers to strip references to cardiovascular disease, breast cancer and probable dementia from the boxed warnings on menopausal hormone therapy products. The agency approved updated labeling for the first products in February 2026. Certain risk details still appear in other parts of the labeling, and systemic estrogen-only products continue to carry a boxed warning concerning endometrial cancer.

According to the MGH Center for Women’s Mental Health, the new ACOG guidance replaced its 2014 recommendations, which had rigidly advised the lowest dose for the shortest time. The 2026 guidelines instead encourage shared, individualized decision-making.

Estrogen plus a progestogen is recommended for women with a uterus to protect the uterine lining; estrogen alone is for those who have had a hysterectomy. People with a prior breast cancer diagnosis, blood clots, stroke, heart attack, active liver disease, unexplained vaginal bleeding or pregnancy are typically not given hormone therapy.

Timing Still Matters

One rule survives the shift: timing. Patients who use HRT typically begin before age 60 or within 10 years of the start of spontaneous menopause, though the MGH center notes that continuing past 60 can still be considered individually to manage ongoing symptoms.

Woman puts estrogen patch on her arm during hormone therapy
Photo: Penn State Health News

On Here & Now on November 17, Dr. Deborah Kwolek, a Menopause Society Certified Practitioner who leads Mass General Brigham’s Sex and Gender Medicine Program, pointed to why the old warnings overstated the risk for many women: the original 2002 study included women with an average age of 63, older than many women who begin hormone therapy today. Current recommendations emphasize a patient’s age, medical history and individual risk factors.

Hormones Aren’t the Only Option

The updated guidelines still recommend nonhormonal treatments for women who can’t or prefer not to use hormones. These include certain antidepressants, neurokinin receptor antagonists such as fezolinetant and elinzanetant — marketed as Veozah and Lynkuet in the U.S. — and nonpharmacological approaches like meditation, cognitive behavioral therapy, acupuncture and hypnosis. Chuang noted the new guidelines address only vasomotor symptoms.

What that means in practice is visible in Chuang’s own clinic. Rebecca G., an Elizabethtown resident who had a hysterectomy at 32, went to her primary care physician when hot flashes hit at 50 — but he wasn’t familiar with HRT or comfortable prescribing it for menopause symptoms.

“I wasn't really paying attention to my cycle. I had no idea whether I was in menopause or not,” she said. “Then, out of nowhere, when I was 50, I started having hot flashes all the time, several times a day and at night.”

Menopause guidance
Photo: TelegraphHerald.com

A coworker recommended Penn State Health’s Menopause Clinic, where Chuang prescribed an estrogen patch. Within weeks, Rebecca noticed fewer hot flashes.

Founded in 1951, the American College of Obstetricians and Gynecologists has grown to represent more than 60,000 obstetrician-gynecologists and women’s health care professionals across the United States and several Latin American countries. In 1986, the organization successfully challenged a Pennsylvania anti-abortion law before the U.S. Supreme Court in Thornburgh v. American College of Obstetricians and Gynecologists, establishing an early legal precedent for reproductive health advocacy.

The Road to the New Guidance

The turnaround unfolded over several years:

  • 2002 — The Women’s Health Initiative links the estrogen-plus-progestin treatment it studied to increased risks of breast cancer, cardiovascular disease, stroke and pulmonary embolism, triggering black-box warnings and a sharp decline in HRT use.
  • November 2025 — After reviewing more recent research, the FDA asks manufacturers to remove cardiovascular disease, breast cancer and probable dementia references from boxed warnings on menopausal hormone therapy products.
  • February 2026 — The FDA approves updated labeling for the first products; an endometrial cancer boxed warning remains for systemic estrogen-only products.
  • October 2026 — The American College of Physicians endorses hormone therapy as a first-line treatment for hot flashes and night sweats.
  • November 2026 — ACOG’s new guidelines recommend HRT as first-line treatment for hot flashes and other vasomotor symptoms, replacing its 2014 guidance.
Photo of author

Health Desk

Health Desk at Archyde.

Saint Michael’s Veteran Bridget McLoughlin Leads Purple Knights Into NCAA Sweet 16 vs. Franklin Pierce